Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma (NCT07777120)
Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting
🩺 Plain-English Summary (8th-Grade Level)
This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.
Who can join: Review the eligibility criteria below.
Location: Center for International Blood and Marrow Transplant Research (CIBMTR) — Milwaukee, Wisconsin
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Center for International Blood and Marrow Transplant Research (CIBMTR) — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Marginal Zone Lymphoma
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma — Duarte, California
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma — Washington D.C., District of Columbia
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) — St Louis, Missouri
- Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma — Duarte, California
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) — Miami, Florida
Explore by condition: All Marginal Zone Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.